← Back to Search
Clinical Applications Of Optical And Optoacoustic Imaging Techniques In The Breast
Published 2018 · Computer Science, Engineering
Save to my Library
Download PDFAnalyze on Scholarcy
Exploitation of the optical properties of tissue to characterize biologic composition has created an era of continuous growth over the past decades for optical imaging. These changes enable the identification of functional abnormalities in conjunction with structural changes of biologic tissue. There is currently a wide array of technologies and applications in development and clinical use. The range of different optical hardware choices has led to systems that utilize optical tissue contrast to address specific clinical needs.
This paper references
Breast cancer detection based on incremental biochemical and physiological properties of breast cancers: a six-year, two-site study.
B. Chance (2005)
In vivo absorption, scattering, and physiologic properties of 58 malignant breast tumors determined by broadband diffuse optical spectroscopy.
A. Cerussi (2006)
Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.
N. Hylton (2016)
Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer
J. F. De Los Santos (2013)
Radiogenomic analysis of breast cancer: luminal B molecular subtype is associated with enhancement dynamics at MR imaging.
M. Mazurowski (2014)
Full-view 3D imaging system for functional and anatomical screening of the breast
A. Oraevsky (2018)
Breast cancer subtype intertumor heterogeneity: MRI‐based features predict results of a genomic assay
E. Sutton (2015)
Correlations between apparent diffusion coefficient values and prognostic factors of breast cancer.
T. Kamitani (2013)
Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy
V. Londero (2004)
Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy.
M. L. Marinovich (2013)
Pretreatment MR Imaging Features of Triple-Negative Breast Cancer: Association with Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival.
M. Bae (2016)
A Pivotal Study of Optoacoustic Imaging to Diagnose Benign and Malignant Breast Masses: A New Evaluation Tool for Radiologists.
E. Neuschler (2018)
Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging.
B. Tromberg (2016)
Diffusion‐weighted imaging of breast cancer: Correlation of the apparent diffusion coefficient value with prognostic factors
S. Kim (2009)
Biomedical Photonics Handbook, 3 Volume Set
T. Vo-Dinh (2014)
Magnetic Resonance Imaging Patterns of Tumor Regression After Neoadjuvant Chemotherapy in Breast Cancer Patients: Correlation With Pathological Response Grading System Based on Tumor Cellularity
T. Kim (2012)
MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer
L. Esserman (2001)
Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer.
S. Park (2010)
Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast
S. H. Park (2010)
Texture analysis in assessment and prediction of chemotherapy response in breast cancer
A. Ahmed (2013)
Diffusion‐weighted breast MRI: Clinical applications and emerging techniques
S. Partridge (2017)
Meta-analysis of quantitative diffusion-weighted MR imaging in the differential diagnosis of breast lesions
X. Chen (2010)
Advanced laser system for 3D optoacoustic tomography of the breast
M. Klosner (2016)
Investigation of iterative image reconstruction in three-dimensional optoacoustic tomography.
K. Wang (2012)
Optical Imaging in Breast Cancer Diagnosis: The Next Evolution
M. Herranz (2012)
I-SPY 1 TRIAL and ACRIN
R. A. Mukhtar (2013)
Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
R. Mukhtar (2013)
Diagnostic accuracy of MRI to evaluate tumour response and residual tumour size after neoadjuvant chemotherapy in breast cancer patients
Alberto Bouzón (2016)